Clustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetes

Diabetes

Volumn 55, Issue 4, 2006, Pages 1133-1140

  Natali, Andrea ^a   Toschi, Elena ^a   Baldeweg, Stephanie ^b   Ciociaro, Demetrio ^a   Favilla, Stefania ^a   Saccà, Luigi ^c   Ferrannini, Ele ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; C REACTIVE PROTEIN; INTERLEUKIN 6; NITROPRUSSIDE SODIUM; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA; VON WILLEBRAND FACTOR;

ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; FIBRINOLYSIS; FOREARM BLOOD FLOW; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; VASCULAR DISEASE; BLOOD; BLOOD FLOW VELOCITY; DRUG EFFECT; FEMALE; FOREARM; GLUCOSE CLAMP TECHNIQUE; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; REFERENCE VALUE; VASCULARIZATION;

ACETYLCHOLINE; BLOOD FLOW VELOCITY; C-REACTIVE PROTEIN; DIABETES MELLITUS, TYPE 2; FEMALE; FOREARM; GLUCOSE CLAMP TECHNIQUE; HUMANS; INFLAMMATION; INFUSIONS, INTRAVENOUS; INSULIN RESISTANCE; INTERLEUKIN-6; MALE; MIDDLE AGED; NITROPRUSSIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; REFERENCE VALUES; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33745324596     PISSN: 00121797     EISSN: 00121797     Source Type: Journal    
DOI: 10.2337/diabetes.55.04.06.db05-1076     Document Type: Article

References (51)

1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106:3143-3421, 2002
2. McNeill AM, Rosamond WD, Girman CJ, Golden SH, Schmidt MI, East HE, Ballantyne CM, Heiss G: The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities study. Diabetes Care 28:385-390, 2005
3. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP: National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation 110:1251-1257, 2004
4. Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB Sr, Wilson PW: C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation 110:380-385, 2004
5. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K: Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 164:1066-1076, 2004
6. Ford ES: The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 173:309-314, 2004
7. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288:2709-2716, 2002
8. Alexander CM, Landsman PB, Teutsch SM, Haffner SM: NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 52:1210-1214, 2003
9. Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S, Runzo C, Prina Cerai S, Pagano G, Cavallo-Perin P: Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diabetes Care 27:2689-2694, 2004
10. Bonora E, Targher G, Formentini G, Calcaterra F, Lombardi S, Marini F, Zenari L, Saggiani F, Poli M, Perbellini S, Raffaelli A, Gemma L, Santi L, Bonadonna RC, Muggeo M: The metabolic syndrome is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diabet Med 21:52-58, 2004
11. Kuusisto J, Lempiainen P, Mykkanen L, Laakso M: Insulin resistance syndrome predicts coronary heart disease events in elderly type 2 diabetic men. Diabetes Care 24:1629-1633, 2001
12. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683-689, 2001
13. Utrianen T, Makimattila S, Virkamaki A, Bergholm R, Yki-Jarvinen H: Dissociation between insulin sensitivity of glucose uptake and endothelial function in normai subjects. Diabetologia 39:1477-1482, 1996
14. Tack C, Ong M, Lutterman J, Smits P: Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance: effects of troglitazone. Diabetologia 41:569-576, 1998
15. Natali A, Taddei S, Quinones-Galvan A, Camastra S, Baldi S, Frascerra S, Virdis S, Sudano I, Salvetti A, Ferrannini E: Insulin sensitivity, vascular reactivity, and clamp-induced vasodilatation in essential hypertension. Circulation 96:849-855, 1997
16. Preik M, Kelm M, Rosen P, Tschope D, Strauer B: Additive effect of coexistent type 2 diabetes and arterial hypertension on endothelial dysfunction in resistance arteries of human forearm vasculature. Angiology 51:545-554, 2000
17. Makimattila S, Liu M-L, Vakkilainen J, Shlenzka A, Lahdenpera S, Syvanne M, Mantysaary M, Summanen P, Bergholm R, Taskinen M-R, Yki-Jarvinen H: Impaired endothelium-dependent vasodilation in type 2 diabetes: relation to LDL size, oxidized LDL, and antioxidants. Diabetes Care 22:973-981, 1999
18. Balletshofer B, Ritting K, Enderle M, Volk A, Maerker E, Jacob S, Matthaei S, Rett K, Haring H: Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 101:1780-1784, 2000
19. Abe H, Yamada N, Kamata K, Kuwaki T, Shimada M, Osuga J, Shionori F, Yahagy N, Kadowaki T, Tamemoto H, Ishibashi S, Yazaki Y, Makuuki M: Hypertension, hypertriglycemia, and impaired endothelium-dependent vascular relation in mice lacking insulin receptor substrate-1. J Clin Invest 101:1784-1788, 1998
20. Shankar RR, Wu Y, Shen HQ, Zhu JS, Baron AD: Mice with gene disruption of both endothelial and neuronal nitric oxide synthase exhibit insulin resistance. Diabetes 49:684-687, 2000
21. Dandona P, Aljada A, Mohanty P, Ghanim H, Hamouda W, Assian E, Ahmad S: Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an antiinflammatory effect? J Clin Endocrinol Metab 86:3257-3265, 2001
22. McLaughlin T, Abbasi F, Lamendola C, Liang L, Reaven G, Schaaf P, Reaven P: Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation 106:2908-2912, 2002
23. Hingorani A, Cross J, Kharbanda R, Mullen M, Bhagat K, Tylor M, Donald A, Palacios M, Griffin G, Deanfield J, MacAllister R, Vallance P: Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation 102:994-999, 2000
24. Tsigos C, Papanicolaou DA, Kyrou I, Defensor R, Mitsiadis CS, Chrousos GP: Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. J Clin Endocrinol Metab 82:4167-4170, 1997
25. Wolfe RR: Radioactive and Stable Isotope Tracers in Biomedicine: Principles and Practice of Kinetic Analysis. New York, John Wiley & Sons, 1992
26. DeFronzo RA, Tobin JD, Andres R: Glucose clamp techique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223, 1979
27. Mari A: Estimation of the rate of appearance in the non-steady state with a two-compartment model. Am J Physiol 263:E400-E415, 1992
28. Hume R: Prediction of lean body mass from height and weight. J Clin Path 19:389-391, 1966
29. Ferrannini E, Natali A, Capaldo B, Lehtovirta M, Jacob S, Yki-Jarvinen H: Insulin resistance, hyperinsulinemia, and blood pressure: role of age and obesity: European Group for the Study of Insulin Resistance (EGIR). Hypertension 30:1144-1149, 1997
30. Maheux P, Jeppesen J, Sheu WH, Hollenbeck CB, Clinkingbeard C, Greenfield MS, Chen YD, Reaven GM: Additive effects of obesity, hypertension, and type 2 diabetes on insulin resistance. Hypertension 24:695-698, 1994
31. Heilbronn LK, Clifton PM: C-reactive protein and coronary artery disease: influence of obesity, caloric restriction and weight loss. J Nutr Biochem 13:316-321, 2002
32. Chambers JC, Eda S, Bassett P, Karim Y, Thompson SG, Gallimore JR, Pepys MB, Kooner JS: C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites. Circulation 104:145-150, 2001
33. Hanley AJ, Festa A, D'Agostino RB Jr, Wagenknecht LE, Savage PJ, Tracy RP, Saad MF, Haffner SM: Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity. Diabetes 53:1773-1781, 2004
34. Perticone F, Ceravolo R, Candigliota M, Ventura G, Iacopino S, Sinopoli F, Mattioli PL: Obesity and body fat distribution induce endothelial dysfunction by oxidative stress: protective effect of vitamin C. Diabetes 50:159-165, 2001
35. McVeigh GE, Brennan GM, Johnston GD, McDermott BJ, McGrath LT, Henry WR, Andrews JW, Hayes JR: Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 35:771-776, 1992
36. Williams SB: Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 27:567-574, 1996
37. Watts GF, O'Brien SF, Silvester W, Millar JA: Impaired endothelium-dependent and independent dilatation of forearm resistance arteries in men with diet-treated non-insulin-dependent diabetes: role of dyslipidaemia. Clin Sci (Lond) 91:567-573, 1996
38. Hogikyan RV, Galecki AT, Pitt B, Halter JB, Greene DA, Supiano MA: Specific impairement of endothelium-dependent vasodilation in subject with type 2 diabetes independent of obesity. J Clin Endocrinol Metab 83:1946-1952, 1998
39. Heitzer T, Krohn K, Albers S, Meinertz T: Tetrahydropterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with type 2 diabetes mellitus. Diabetologia 43:1435-1438, 2000
40. Chowienczyk P, Brett S, Gopaul N, Meeking D, Marchetti M, Russell-Jones D, Anggard E, Ritter J: Oral treatment with an antioxidant (raxofelast) reduces oxidative stress and improves endothelial function in men with type 2 diabetes. Diabetologia 43:974-977, 2000
41. Vehkavaara S, Makimattila S, Schlenzka A, Vakkilainen J, Westerbacka J, Yki-Jarvinen: Insulin therapy improves endothelial function in type 2 diabetes. Arterioclers Thromb Vasc Biol 20:545-550, 2000
42. Trovati M, Anfossi G: Influence of insulin and of insulin resistance on platelet and vascular smooth muscle cell function. J Diabetes Complications 16:35-40, 2002
43. Natali A, Baldeweg S, Toschi E, Capaldo B, Barbaro D, Gastaldelli A, Yudkin JS, Ferrannini E: Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care 27:1349-1357, 2004
44. Hsueh WA, Lyon CJ, Quinones MJ: Insulin resistance and the endothelium. Am J Med 117:109-117, 2004
45. Stuhlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, Reaven GM, Tsao PS: Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 287:1420-1426, 2002
46. Meigs JB, Jacques PF, Selhub J, Singer DE, Nathan DM, Rifai N, D'Agostino RB Sr, Wilson PW: Fasting plasma homocysteine levels in the insulin resistance syndrome: the Framingham Offspring Study. Diabetes Care 24:1403-1410, 2001
47. Emoto M, Kanda H, Shoji T, Kawagishi T, Komatsu M, Mori K, Tahara H, Ishimura E, Inaba M, Okuno Y, Nishizawa Y: Impact of insulin resistance and nephropathy on homocysteine in type 2 diabetes. Diabetes Care 24:533-538, 2001
48. Steinberg HO, Tarshoby M, Monestel R, Hook G, Cronin J, Johnson A, Bayazeed B, Baron AD: Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest 100:1230-1239, 1997
49. Natali A, Nannipieri M, Ferrannini E: Effects of insulin on the kidney and the cardiovascular system. In The Kidney and Hypertension in Diabetes Mellitus. 6th ed. Mogensen C, Ed. Norwell, MA, Kluwer Academic, 2004, p.425-438
50. Mather K, Verma S, Anderson T: Improved endothelial function with metformin in type 2 diabetes mellitus. J Am Coll Cardiol 37:1344-1350, 2001
51. van Etten RW, de Koning EJ, Verhaar MC, Gaillard CA, Rabelink TJ: Impaired NO-dependent vasodilation in patients with type II (non-insulin- dependent) diabetes mellitus is restored by acute administration of folate. Diabetologia 45:1004-1010, 2002